X-linked hypophosphatemia explained

X-linked hypophosphatemia
Synonyms:X-linked dominant hypophosphatemic rickets, or X-linked Vitamin D-resistant rickets,
Complications:osteomalacia (adults), rickets (children), fractures, enthesopathy, spinal stenosis, abnormal gait, short stature, tinnitus, hearing loss, dental complications, in rare exceptions Chiari malformation can occur.
Causes:A genetic mutation of the PHEX gene results in elevated FGF23 hormone.
Medication:phosphate, vitamin-D or burosumab

X-linked hypophosphatemia (XLH) is an X-linked dominant form of rickets (or osteomalacia) that differs from most cases of dietary deficiency rickets in that vitamin D supplementation does not cure it. It can cause bone deformity including short stature and genu varum (bow-leggedness). It is associated with a mutation in the PHEX gene sequence (Xp.22) and subsequent inactivity of the PHEX protein. PHEX mutations lead to an elevated circulating (systemic) level of the hormone FGF23 which results in renal phosphate wasting,[1] and local elevations of the mineralization/calcification-inhibiting protein osteopontin in the extracellular matrix of bones and teeth.[2] [3] An inactivating mutation in the PHEX gene results in an increase in systemic circulating FGF23, and a decrease in the enzymatic activity of the PHEX enzyme which normally removes (degrades) mineralization-inhibiting osteopontin protein; in XLH, the decreased PHEX enzyme activity leads to an accumulation of inhibitory osteopontin locally in bones and teeth to block mineralization which, along with renal phosphate wasting, both cause osteomalacia and odontomalacia.[4] [5]

For both XLH and hypophosphatasia, inhibitor-enzyme pair relationships function to regulate mineralization in the extracellular matrix through a double-negative (inhibiting the inhibitors) activation effect in a manner described as the Stenciling Principle.[6] [7] Both these underlying mechanisms (renal phosphate wasting systemically, and mineralization inhibitor accumulation locally) contribute to the pathophysiology of XLH that leads to soft bones and teeth (hypomineralization, osteomalacia/odontomalacia).[8] [9] [10] The prevalence of the disease is 1 in 20,000.[11]

X-linked hypophosphatemia may be lumped in with autosomal dominant hypophosphatemic rickets under general terms such as hypophosphatemic rickets. Hypophosphatemic rickets are associated with at least nine other genetic mutations. Clinical management of hypophosphatemic rickets may differ depending on the specific mutations associated with an individual case, but treatments are aimed at raising phosphate levels to promote normal bone formation.[12]

Symptoms and signs

The most common symptoms of XLH affect the bones and teeth, causing pain, abnormalities, and osteoarthritis. Symptoms and signs can vary between children and adults and can include (but not limited to):

Children

Adults

Genetics

XLH affects about 1:20,000 individuals and is the most common cause of inherited phosphate wasting.[22]

It is associated with a mutation in the PHEX gene sequence, located on the human X chromosome at location Xp22.2-p22.1. The PHEX protein regulates another protein called fibroblast growth factor 23 (produced from the FGF23 gene). Fibroblast growth factor 23 normally inhibits the kidneys' ability to reabsorb phosphate into the bloodstream. Gene mutations in PHEX prevent it from correctly regulating fibroblast growth factor 23. The overactivity of FGF-23 reduces vitamin D 1α-hydroxylation and phosphate reabsorption by the kidneys, leading to hypophosphatemia and the related features of ricket.[25] Also in XLH, where PHEX enzymatic activity is absent or reduced, osteopontin[26] —a mineralization-inhibiting secreted substrate protein found in the extracellular matrix of bone[27] —accumulates in bone (and teeth) to contribute to the osteomalacia (and odontomalacia) as shown in the mouse homolog (Hyp) of XLH and in XLH patients.[28] [29] [30]

The disorder is inherited in an X-linked dominant manner.[31] This means the defective gene responsible for the disorder (PHEX) is located on the X chromosome, and only one copy of the defective gene is sufficient to cause the disorder when inherited from a parent who has the disorder. Males are normally hemizygous for the X chromosome, having only one copy. As a result, X-linked dominant disorders usually show higher expressivity in males than females.

As the X chromosome is one of the sex chromosomes (the other being the Y chromosome), X-linked inheritance is determined by the sex of the parent carrying a specific gene and can often seem complex. This is because, typically, females have two copies of the X-chromosome and males have only one copy. The difference between dominant and recessive inheritance patterns also plays a role in determining the chances of a child inheriting an X-linked disorder from their parentage.

Diagnosis

The clinical laboratory evaluation of rickets begins with assessment of serum calcium, phosphate, and alkaline phosphatase levels. In hypophosphatemic rickets, calcium levels may be within or slightly below the reference range; alkaline phosphatase levels will be significantly above the reference range.Biochemically, XLH is recognized by hypophosphatemia.[32]

Carefully evaluate serum phosphate levels in the first year of life, because the concentration reference range for infants (5.0–7.5 mg/dL) is high compared with that for adults (2.7–4.5 mg/dL).

Serum parathyroid hormone levels are within the reference range or slightly elevated. calcitriol (1,25-(OH)2 vitamin D3) levels are low or within the lower reference range. Most importantly, urinary loss of phosphate is above the reference range.

The renal tubular reabsorption of phosphate (TRP) in X-linked hypophosphatemia is 60%; normal TRP exceeds 90% at the same reduced plasma phosphate concentration. The TRP is calculated with the following formula:

1 − [Phosphate Clearance (C<sub>P<sub>i</sub></sub>) / Creatinine Clearance (C<sub>cr</sub>)] × 100

Treatment

Conventional therapy consisted of medications including human growth hormone, calcitriol, and oral phosphate,[33] [34] and calcitriol; Unwanted effects of this therapy have included secondary hyperparathyroidism, nephrocalcinosis, kidney stones, and cardiovascular abnormalities.

In February 2018 the European Medicines Agency first licensed a monoclonal antibody directed against FGF23, the first drug targeting the underlying cause for this condition,[35] called burosumab.[36] It was then licensed by the US Food and Drug Administration in June 2018[37]

The leg deformity can be treated with Ilizarov frames and CAOS.In the event of severe bowing, an osteotomy can be performed to correct the leg shape.[38]

Society and culture

International XLH Alliance – an alliance of international patient groups for individuals affected by XLH and related disorders.

Jennyfer Marques Parinos is a Paralympic bronze medalist from Brazil who has XLH. She competes under a class 9 disability.

See also

Notes and References

  1. Book: Carpenter TO . Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP. 6. Primary Disorders of Phosphate Metabolism. Endotext. MDText.com, Inc.. South Dartmouth, Massachusetts. 8 June 2022. 25905395. National Library of Medicine Bookshelf ID NBK279172.
  2. Barros . NM . Hoac . B . Neves . RL . Addison . WN . Assis . DM . Murshed . M . Carmona . AK . McKee . MD . Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. . Journal of Bone and Mineral Research . March 2013 . 28 . 3 . 688–99 . 10.1002/jbmr.1766 . 22991293. 20840491 . free .
  3. Boukpessi . T . Hoac . B . Coyac . BR . Leger . T . Garcia . C . Wicart . P . Whyte . MP . Glorieux . FH . Linglart . A . Chaussain . C . McKee . MD . Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. . Bone . February 2017 . 95 . 151–161 . 10.1016/j.bone.2016.11.019 . 27884786.
  4. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia . 2017 . 27884786. Boukpessi . T. . Hoac . B. . Coyac . B. R. . Leger . T. . Garcia . C. . Wicart . P. . Whyte . M. P. . Glorieux . F. H. . Linglart . A. . Chaussain . C. . McKee . M. D. . Bone . 95 . 151–161 . 10.1016/j.bone.2016.11.019 .
  5. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia . 2013 . 22991293. Barros . N. M. . Hoac . B. . Neves . R. L. . Addison . W. N. . Assis . D. M. . Murshed . M. . Carmona . A. K. . McKee . M. D. . Journal of Bone and Mineral Research . 28 . 3 . 688–699 . 10.1002/jbmr.1766 . 20840491 . free .
  6. Biological stenciling of mineralization in the skeleton: Local enzymatic removal of inhibitors in the extracellular matrix . 2020 . 32454257. Reznikov . N. . Hoac . B. . Buss . D. J. . Addison . W. N. . Barros NMT . McKee . M. D. . Bone . 138 . 115447 . 10.1016/j.bone.2020.115447 . 218909350 .
  7. Mineral tessellation in bone and the Stenciling Principle for extracellular matrix mineralization . 2022 . 34915130. McKee . M. D. . Buss . D. J. . Reznikov . N. . Journal of Structural Biology . 214 . 1 . 107823 . 10.1016/j.jsb.2021.107823 . 245187449 .
  8. McKee . MD . Buss . DJ . Reznikov . N . Mineral tessellation in bone and the stenciling principle for extracellular matrix mineralization. . Journal of Structural Biology . December 13, 2021 . 214 . 1 . 107823 . 10.1016/j.jsb.2021.107823 . 34915130. 245187449 .
  9. McKee . MD . Hoac . B . Addison . WN . Barros . NM . Millán . JL . Chaussain . C . Extracellular matrix mineralization in periodontal tissues: Noncollagenous matrix proteins, enzymes, and relationship to hypophosphatasia and X-linked hypophosphatemia. . Periodontology 2000 . October 2013 . 63 . 1 . 102–22 . 10.1111/prd.12029 . 23931057. 3766584 .
  10. Buss . DJ . Reznikov . N . McKee . MD . Crossfibrillar mineral tessellation in normal and Hyp mouse bone as revealed by 3D FIB-SEM microscopy. . Journal of Structural Biology . November 1, 2020 . 212 . 2 . 107603 . 10.1016/j.jsb.2020.107603 . 32805412. 221164596 .
  11. Carpenter TO . New perspectives on the biology and treatment of X-linked hypophosphatemic rickets . Pediatr. Clin. North Am. . 44 . 2 . 443–466 . Apr 1997 . 9130929 . 10.1016/S0031-3955(05)70485-5. free .
  12. Web site: Hypophosphatemic rickets . Genetic and Rare Diseases Information Center . National Institutes of Health . October 10, 2012 . https://web.archive.org/web/20120612101237/http://rarediseases.info.nih.gov/GARD/Disease.aspx?PageID=4&diseaseID=6735 . June 12, 2012 . dead .
  13. Web site: Osteomalacia and Rickets. The Lecturio Medical Concept Library . August 24, 2021.
  14. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocrine Connections. 2014. 3. R13–R30. 3959730. Linglart. A.. Biosse-Duplan. M.. Briot. K.. Chaussain. C.. Esterle. L.. Guillaume-Czitrom. S.. Kamenicky. P.. Nevoux. J.. Prié. D.. Rothenbuhler. A.. Wicart. P.. Harvengt. P.. 1. 10.1530/EC-13-0103. 24550322.
  15. Buss . Daniel J. . Rechav . Katya . Reznikov . Natalie . McKee . Marc D. . September 2023 . Mineral tessellation in mouse enthesis fibrocartilage, Achilles tendon, and Hyp calcifying enthesopathy: A shared 3D mineralization pattern . Bone . 174 . 116818 . 10.1016/j.bone.2023.116818 . 37295663 . 259131061 . 8756-3282.
  16. Web site: Fatigue . MedlinePlus . April 30, 2020.
  17. Web site: Overview of Bone Fractures. The Lecturio Medical Concept Library . August 24, 2021.
  18. Luger, N. Mach, D. Sevcik, M. Mantyh, P. (2005). Bone cancer pain: From mechanism to model to therapy. Journal of Pain and Symptom Management. 29(5): 32-46.
  19. Web site: Osteoarthritis. The Lecturio Medical Concept Library . August 24, 2021.
  20. The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey. Journal of the Endocrine Society. 2019. 3. 1321–1334. 6595532. Skrinar. A.. Dvorak-Ewell. M.. Evins. A.. MacIca. C.. Linglart. A.. Imel. E. A.. Theodore-Oklota. C.. San Martin. J.. 7. 10.1210/js.2018-00365. 31259293.
  21. Higher prevalence of non-skeletal comorbidity related to X-linked hypophosphataemia: a UK parallel cohort study using CPRD . Rheumatology. 2020. 60. 4055–4062. 33331900. Hawley. S.. Shaw. N. J.. Delmestri. A.. Prieto-Alhambra. D.. Cooper. C.. Pinedo-Villanueva. R.. Javaid. M. K.. 9. 10.1093/rheumatology/keaa859.
  22. Beck-Nielsen . Signe Sparre . Mughal . Zulf . Haffner . Dieter . Nilsson . Ola . Levtchenko . Elena . Ariceta . Gema . de Lucas Collantes . Carmen . Schnabel . Dirk . Jandhyala . Ravi . Mäkitie . Outi . February 26, 2019 . FGF23 and its role in X-linked hypophosphatemia-related morbidity . Orphanet Journal of Rare Diseases . 14 . 1 . 58 . 10.1186/s13023-019-1014-8 . 1750-1172 . 6390548 . 30808384 . free .
  23. Buss . Daniel J. . Reznikov . Natalie . McKee . Marc D. . November 2020 . Crossfibrillar mineral tessellation in normal and Hyp mouse bone as revealed by 3D FIB-SEM microscopy . Journal of Structural Biology . 212 . 2 . 107603 . 10.1016/j.jsb.2020.107603 . 32805412 . 221164596 . 1047-8477.
  24. Buss . Daniel J. . Rechav . Katya . Reznikov . Natalie . McKee . Marc D. . September 2023 . Mineral tessellation in mouse enthesis fibrocartilage, Achilles tendon, and Hyp calcifying enthesopathy: A shared 3D mineralization pattern . Bone . 174 . 116818 . 10.1016/j.bone.2023.116818 . 37295663 . 259131061 . 8756-3282.
  25. Perwad. Farzana. Zhang. Martin Y. H.. Tenenhouse. Harriet S.. Portale. Anthony A.. November 1, 2007. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. American Journal of Physiology. Renal Physiology. 293. 5. F1577–1583. 10.1152/ajprenal.00463.2006. 1931-857X. 17699549. 20559055 .
  26. Sodek. J. Osteopontin. Critical Reviews in Oral Biology and Medicine. 2000. 11. 3. 279–303. 11021631. 10.1177/10454411000110030101. etal. free.
  27. McKee. MD. Hierarchies of extracellular matrix and mineral organization in bone of the craniofacial complex and skeleton. Cells Tissues Organs. 2005. 181. 3–4. 176–188. 16612083. 10.1159/000091379. 40705942. etal.
  28. McKee. MD. Hoac. B. Addison. WN. Barros. NM. Millán. JL. Chaussain. C. Extracellular matrix mineralization in periodontal tissues: Noncollagenous matrix proteins, enzymes, and relationship to hypophosphatasia and X-linked hypophosphatemia. Periodontology 2000. October 2013. 63. 1. 102–22. 23931057. 10.1111/prd.12029. 3766584.
  29. Boukpessi. T. Hoac. B. Coyac. BR. Leger. T. Garcia. C. Wicart. P. Whyte. MP. Glorieux. FH. Linglart. A. Chaussain. C. McKee. MD. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone. November 21, 2016. 95. 151–161. 27884786. 10.1016/j.bone.2016.11.019.
  30. Barros. NMT. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. Journal of Bone and Mineral Research. 2013. 28. 3. 688–699. 22991293. 10.1002/jbmr.1766. etal. free.
  31. Saito . T. . Nishii . Y. . Yasuda . T. . Ito . N. . Suzuki . H. . Igarashi . T. . Fukumoto . S. . Fujita . T.. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. European Journal of Endocrinology. 161. 4. 647–651. Oct 2009. 19581284. 10.1530/EJE-09-0261. free .
  32. Haffner . Dieter . Emma . Francesco . Eastwood . Deborah M. . Duplan . Martin Biosse . Bacchetta . Justine . Schnabel . Dirk . Wicart . Philippe . Bockenhauer . Detlef . Santos . Fernando . Levtchenko . Elena . Harvengt . Pol . Kirchhoff . Martha . Di Rocco . Federico . Chaussain . Catherine . Brandi . Maria Louisa . July 2019 . Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia . Nature Reviews Nephrology . en . 15 . 7 . 435–455 . 10.1038/s41581-019-0152-5 . 31068690 . 7136170 . 1759-507X.
  33. Imel. E. A.. DiMeglio, L. A. . Hui, S. L. . Carpenter, T. O. . Econs, M. J. . Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations. Journal of Clinical Endocrinology & Metabolism. February 15, 2010. 95. 4. 1846–1850. 10.1210/jc.2009-1671. 20157195. 2853995.
  34. Glorieux. F. H.. Marie, P. J. . Pettifor, J. M. . Delvin, E. E. . Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. The New England Journal of Medicine. October 30, 1980. 303. 18. 1023–1031. 10.1056/NEJM198010303031802. 6252463.
  35. Carpenter. TO. Whyte MP . Imel EA . Boot AM . Högler W . Linglart A . Padidela R . Van't Hoff W . Mao M . Chen CY . Skrinar A . Kakkis E . San Martin J . Portale AA . Burosumab Therapy in Children with X-Linked Hypophosphatemia. The New England Journal of Medicine. May 24, 2018. 378. 21. 1987–1998. 10.1056/NEJMoa1714641. 29791829. Submitted manuscript. 1805/18603. 44135503. free.
  36. Web site: September 17, 2018. EMA authorisation details.
  37. News: FDA press release.
  38. Web site: X-linked hypophosphatemia Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. rarediseases.info.nih.gov. en. October 21, 2018.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "X-linked hypophosphatemia".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.